ZMYND11 and prostate cancer: Altogether, our data elucidate the oncogenic and clinical impacts of HNRNPA1 on prostate cancer progression and demonstrate that ZMYND11 attenuates the oncogenic capabilities of HNRNPA1 through binding mediated by the MYND domain of ZMYND11.